Enlivex Therapeutics Stock Buy Hold or Sell Recommendation
| ENLV Stock | USD 1.32 0.08 5.71% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Enlivex Therapeutics is 'Cautious Hold'. Macroaxis provides Enlivex Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ENLV positions. The advice algorithm takes into account all of Enlivex Therapeutics' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Enlivex Therapeutics' buy or sell advice are summarized below:
Real Value 4.04 | Target Price 12 | Hype Value 1.27 | Market Value 1.32 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Enlivex Therapeutics given historical horizon and risk tolerance towards Enlivex Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for Enlivex Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Enlivex |
Execute Enlivex Therapeutics Buy or Sell Advice
The Enlivex recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Enlivex Therapeutics. Macroaxis does not own or have any residual interests in Enlivex Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Enlivex Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Enlivex Therapeutics Trading Alerts and Improvement Suggestions
| Enlivex Therapeutics generated a negative expected return over the last 90 days | |
| Enlivex Therapeutics has high historical volatility and very poor performance | |
| Enlivex Therapeutics may become a speculative penny stock | |
| Net Loss for the year was (29.07 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Enlivex Therapeutics currently holds about 62.48 M in cash with (23.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.4, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Enlivex Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from globenewswire.com: Enlivex Announces Authorization from the Danish Regulatory Agency for the Companys Randomized, Controlled Phase III Trial Evaluating Allocetra in Patients with Knee Osteoarthritis |
Enlivex Therapeutics Returns Distribution Density
The distribution of Enlivex Therapeutics' historical returns is an attempt to chart the uncertainty of Enlivex Therapeutics' future price movements. The chart of the probability distribution of Enlivex Therapeutics daily returns describes the distribution of returns around its average expected value. We use Enlivex Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Enlivex Therapeutics returns is essential to provide solid investment advice for Enlivex Therapeutics.
| Mean Return | -0.52 | Value At Risk | -12.76 | Potential Upside | 11.68 | Standard Deviation | 9.24 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Enlivex Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Enlivex Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Enlivex Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Enlivex Therapeutics backward and forwards among themselves. Enlivex Therapeutics' institutional investor refers to the entity that pools money to purchase Enlivex Therapeutics' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Advisor Group Holdings, Inc. | 2023-12-31 | 400 | Bank Of America Corp | 2023-12-31 | 266 | Jpmorgan Chase & Co | 2023-12-31 | 237 | Advisory Services Network, Llc | 2023-12-31 | 43.0 | Qube Research & Technologies | 2023-12-31 | 1.0 | Goldman Sachs Group Inc | 2023-09-30 | 0.0 | Srs Capital Advisors Inc | 2023-09-30 | 0.0 | Susquehanna International Group Ltd | 2023-12-31 | 0.0 | Simplex Trading, Llc | 2023-09-30 | 0.0 | Renaissance Technologies Corp | 2023-12-31 | 62.1 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 44.5 K |
Enlivex Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Capital Expenditures | 193K | 1.0M | 1.6M | 8.1M | 236K | 224.2K | |
| Change In Cash | (4.3M) | 1.5M | 4.6M | 38.7M | (49.0M) | (46.6M) | |
| Free Cash Flow | (7.2M) | (12.0M) | (19.2M) | (32.1M) | (23.8M) | (22.6M) | |
| Net Income | (9.4M) | (11.8M) | (14.5M) | (31.1M) | (29.1M) | (27.6M) | |
| End Period Cash Flow | 5.5M | 7.0M | 11.6M | 50.4M | 926K | 879.7K | |
| Other Non Cash Items | 168K | 167K | 413K | 2.8M | 6.5M | 6.9M | |
| Depreciation | 206K | 286K | 546K | 777K | 835K | 876.8K | |
| Investments | (6.4M) | (20.0M) | (36.8M) | 62.5M | (33.0M) | (31.3M) | |
| Change To Netincome | 1.0M | 576K | (2.3M) | 5.5M | 6.4M | 6.7M |
Enlivex Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Enlivex Therapeutics or Software sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Enlivex Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Enlivex stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.65 | |
β | Beta against NYSE Composite | 2.03 | |
σ | Overall volatility | 9.41 | |
Ir | Information ratio | -0.06 |
Enlivex Therapeutics Volatility Alert
Enlivex Therapeutics is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Enlivex Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Enlivex Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Enlivex Therapeutics Fundamentals Vs Peers
Comparing Enlivex Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Enlivex Therapeutics' direct or indirect competition across all of the common fundamentals between Enlivex Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Enlivex Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Enlivex Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Enlivex Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Enlivex Therapeutics to competition |
| Fundamentals | Enlivex Therapeutics | Peer Average |
| Return On Equity | -0.67 | -0.31 |
| Return On Asset | -0.3 | -0.14 |
| Current Valuation | 1.24 M | 16.62 B |
| Shares Outstanding | 18.6 M | 571.82 M |
| Shares Owned By Insiders | 11.80 % | 10.09 % |
| Shares Owned By Institutions | 8.93 % | 39.21 % |
| Number Of Shares Shorted | 236.38 K | 4.71 M |
| Price To Earning | (11.97) X | 28.72 X |
| Price To Book | 0.76 X | 9.51 X |
| EBITDA | (24.09 M) | 3.9 B |
| Net Income | (29.07 M) | 570.98 M |
| Cash And Equivalents | 62.48 M | 2.7 B |
| Cash Per Share | 3.40 X | 5.01 X |
| Total Debt | 1.03 M | 5.32 B |
| Debt To Equity | 0.08 % | 48.70 % |
| Current Ratio | 15.44 X | 2.16 X |
| Book Value Per Share | 1.62 X | 1.93 K |
| Cash Flow From Operations | (23.52 M) | 971.22 M |
| Short Ratio | 2.38 X | 4.00 X |
| Earnings Per Share | (1.47) X | 3.12 X |
| Target Price | 7.0 | |
| Beta | 1.06 | -0.15 |
| Market Capitalization | 27.53 M | 19.03 B |
| Total Asset | 36.83 M | 29.47 B |
| Retained Earnings | (112.09 M) | 9.33 B |
| Working Capital | 45.72 M | 1.48 B |
| Current Asset | 6 M | 9.34 B |
| Current Liabilities | 671.32 K | 7.9 B |
| Net Asset | 36.83 M |
Enlivex Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Enlivex . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 12507.4 | |||
| Daily Balance Of Power | (0.50) | |||
| Rate Of Daily Change | 0.94 | |||
| Day Median Price | 1.31 | |||
| Day Typical Price | 1.31 | |||
| Price Action Indicator | (0.03) | |||
| Period Momentum Indicator | (0.08) |
About Enlivex Therapeutics Buy or Sell Advice
When is the right time to buy or sell Enlivex Therapeutics? Buying financial instruments such as Enlivex Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 3.2M | 4.0M | 4.9M | 5.1M | Total Assets | 95.1M | 67.6M | 36.8M | 30.6M |
Use Investing Ideas to Build Portfolios
In addition to having Enlivex Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Preferred Stock ETFs Thematic Idea Now
Preferred Stock ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Preferred Stock ETFs theme has 15 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Preferred Stock ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Enlivex Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Enlivex Stock please use our How to Invest in Enlivex Therapeutics guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Complementary Tools for Enlivex Stock analysis
When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |
Is Enlivex Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enlivex Therapeutics. If investors know Enlivex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enlivex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.47) | Return On Assets (0.30) | Return On Equity (0.67) |
The market value of Enlivex Therapeutics is measured differently than its book value, which is the value of Enlivex that is recorded on the company's balance sheet. Investors also form their own opinion of Enlivex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enlivex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enlivex Therapeutics' market value can be influenced by many factors that don't directly affect Enlivex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enlivex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enlivex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enlivex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.